Angiotensin converting enzyme (ACE) is one of a number of integral membrane proteins that is proteolytically shed from the cell surface by a zinc metallosecretase. Mutagenesis of Asn631 to Gln in the juxtamembrane stalk region of ACE resulted in more efficient secretion of the mutant protein (ACE NQ ) as determined by pulse-chase analysis. In contrast to wild type ACE, the cleavage of ACE NQ was not blocked by the metallosecretase inhibitor batimastat but by the serine protease inhibitor, 1,3-dichloroisocoumarin. Incubation of the cells at 15 o C revealed that ACE NQ was cleaved in the endoplasmic reticulum, and mass spectrometric analysis of the secreted form of the protein indicated that it had been cleaved at the Asn635-Ser636 bond, three residues N-terminal to the normal secretase cleavage site at Arg638-Ser639. These data clearly show that a point mutation in the juxtamembrane region of an integral membrane protein can invoke the action of a mechanistically and spatially distinct secretase. In the light of this observation, previous data on the effect of mutations in the juxtamembrane stalk of shed proteins being accommodated by a single secretase having a relaxed specificity need to be re-evaluated.
Introduction
Angiotensin converting enzyme (ACE; EC 3.4.15.1) plays a key role in the control of blood pressure and fluid and electrolyte homeostasis (1) . It exists primarily as a type I integral membrane glycoprotein, although a soluble form is present under normal conditions in blood plasma and other body fluids which is derived from the membrane-bound form through proteolytic cleavage in the juxtamembrane stalk region (2) . The secretase responsible for the cleavage and secretion of ACE is a zinc metalloproteinase, located at the cell surface (3) (4) (5) (6) . It is inhibited by hydroxamate-based compounds such as batimastat, and displays a remarkably similar inhibition profile to that of the α-secretase that cleaves the amyloid precursor protein (7, 8) . The precise site of cleavage in ACE has been determined by matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry following enzymic fragmentation of the purified protein (9) . This analysis revealed that the soluble somatic forms of human and porcine ACE were cleaved between Arg1203-Ser1204, some 27 residues on the extracellular side of the transmembrane domain.
ACE is just one of several proteins that are post-translationally shed from the membrane through the action of secretases (also called sheddases or convertases) (10) (11) (12) . Other proteins proteolytically cleaved from the membrane include tumour necrosis factor-α, transforming growth factor-α, amyloid precursor protein and L-selectin. The secretases that cleave and release such proteins from the membrane have several properties in common, including up-regulation by phorbol esters and inhibition by hydroxamate-based zinc metalloproteinase inhibitors.
Numerous studies have investigated the sequence/structural requirements for recognition of an integral membrane protein by its cognate secretase (for example [13] [14] [15] [16] [17] [18] . This has usually been investigated by mutating residues in the extracellular juxtamembrane stalk region and monitoring their effect on secretion of the expressed protein. Such studies, in which numerous by guest on October 5, 2017 http://www.jbc.org/ Downloaded from 4 mutations failed to abrogate cleavage and secretion of the membrane protein, have concluded that for each substrate protein there is a single secretase with a relaxed sequence specificity, and that the critical parameter for cleavage efficiency is the relative conformation (possibly α-helical) of the stalk region. However, an alternative explanation for these observations is that the mutations in the juxtamembrane stalk invoked the action of other, distinct secretases. The involvement of multiple secretases was suggested by Zhong et al. (19) when numerous point mutations in the stalk region of the amyloid precursor protein resulted in that protein being cleaved at multiple sites, although there was no experimental evidence (inhibition profile, cellular location) to support this suggestion.
Here we report that a single point mutation in the juxtamembrane stalk region of ACE invokes the action of a mechanistically and spatially distinct secretase. Asn631 in the single domain form of ACE (20) (corresponding to Asn1196 in human somatic ACE), 7 residues N-terminal to the normal secretase cleavage site, was mutated to Gln (Fig. 1) . The mutant protein (ACE NQ ) was transport-competent and enzymatically active, indicating that the mutation has no general effects on the folding of ACE. Pulse-chase analysis revealed that ACE NQ was more readily cleaved and secreted into the medium than the wild type protein. Mass spectrometric analysis of the secreted protein, and temperature block and inhibitor studies indicated that ACE NQ was being cleaved between Asn635 and Ser636 in the endoplasmic reticulum (ER) by a serine protease, and not between Arg638 and Ser639 at the cell-surface by the batimastat-sensitive metallosecretase. In the light of this observation, the conclusions of earlier studies investigating the sequence requirements of various secretases through analysis of the effect of mutations on the secretion of the substrate protein require re-evaluation, and should not be interpreted solely in the context of a single protease activity having a relaxed specificity. 
Experimental

Construction of ACE NQ
The expression vector pECE containing a C-terminal fragment of human ACE in which the Nterminal signal peptide was fused with the C-terminal domain (pECE hACE) (20) was used. In this construct the membrane-proximal stalk region, transmembrane and cytosolic domains are identical to those in human somatic ACE. Asn631 (Fig. 1 mg/ml streptomycin (denoted Met-free medium). In pulse-chase experiments labeling was performed for 1 h at 37°C followed by a chase with non-labeled Met for different periods of time. The labeled cells were rinsed twice with PBS prior to harvesting. Cells were subjected to phase separation in Triton X-114 essentially as described by Wilson et al. (22) .
Immunoprecipitation and SDS PAGE
Cells were solubilized with 1ml/dish of cold lysis buffer (25 mM Tris/HCl, pH 8.0, 50 mM NaCl, 0.5% Triton X-100, and 0.5% sodium deoxycholate) and the cell extracts were centrifuged at 10,000g for 15 min to remove nuclei and debris. Thereafter the supernatants were incubated with the rabbit anti-ACE polyclonal antibody (RP183) (23) and precipitated with protein A-Sepharose. Following immunoprecipitation, the protein A-Sepharose beads were washed 3 times with washing buffer A (0.5% Triton X-100, 0.05% sodium deoxycholate in PBS) and 3 times with washing buffer B (500 mM NaCl, 10 mM EDTA, 0.5% Triton X-100 in 125 mM Tris/HCl, pH 8.0) prior to analysis of the samples by SDS-PAGE and fluorography as described previously (24) . The digestion of [ 35 S]-labeled immunoprecipitates with endo-ß-Nacetylglucosaminidase H (endo H) and endo-ß-N-acetylglucosaminidase F/glycopeptidase F (endo F) was performed as previously described (24) . BzGly was separated from the substrate and quantitated by reverse phase HPLC as described previously (25) .
Isolation and mass spectral analysis of secreted ACE
Medium was collected from IMR32 cells transiently transfected with either pECE hACE or pECE hACE NQ , centrifuged at 3000g for 5 min and then concentrated in a stirred ultrafiltration cell (Amicon) using a 10 kDa cut-off membrane. The samples were then dialysed overnight against 10 mM Hepes/NaOH, 0.3 M KCl, 0.1 mM ZnCl 2 , pH 7.5. ACE was then isolated by affinity chromatography on lisinopril-2.8 nm-Sepharose as described previously (26) . The enzyme was eluted from the affinity column with 0.1 M sodium borate, pH 9.5, dialysed and concentrated using Centricon 10 kDa cut-off filters (Vivascience, Cambridge, UK). Purified secreted wtACE and ACE NQ proteins were reduced and protected with vinyl pyridine prior to digestion with endoproteinase Lys-C. The total digest was analysed directly by MALDI-TOF mass spectrometry, or the digest was first fractionated by HPLC and the C-terminal peptide was identified by automated N-terminal peptide sequencing, before mass spectral analysis (27, 28 2) . wtACE was present in the medium, consistent with its release from the cell-surface by the batimastat-sensitive secretase (Fig. 2) . The ACE NQ mutant was also detected in the medium from the cells, and indeed the relative ratio of ACE protein in the medium compared with the cell lysate appeared greater for the mutant as compared to the wild type protein. Deglycosylation with EndoF revealed that both wtACE and ACE NQ were N-glycosylated (Fig. 2 ).
Deglycosylation revealed that there was a distinct difference in size between wtACE in the cell lysate as compared with that secreted into the medium, consistent with removal of the Cterminal transmembrane and cytosolic domains of the protein by the secretase (9) . Interestingly, such a size difference was not apparent between the cell lysate and medium samples of ACE NQ (Fig. 2) .
ACE NQ is secreted into the medium faster than wild type ACE
The rate at which ACE NQ was secreted into the medium compared to that of wild type ACE was assessed by pulse-chase labelling ( Fig. 3) . wtACE appeared in the medium after 4 hr of chase, consistent with previous reports using other cell lines (27, 29) . At 6 hr of chase a considerable amount of wtACE was still present in the cell lysate. In contrast ACE NQ was detected in the medium from the cells after 30 min of chase. After 4 hr of chase the majority of ACE NQ had been secreted from the cell and was no longer present in the lysate sample. The apparent larger size of the medium form of the mutant protein compared to that in the lysate is due to complex by guest on October 5, 2017
http://www.jbc.org/ Downloaded from 9 glycosylation of the protein as it traffics along the secretory pathway. The mutant ACE NQ detected in the cell lysate is mannose-rich glycosylated as assessed by its complete sensitivity towards endo H, while the ACE NQ species secreted into the medium was endo H resistant indicating that it has acquired complex type glycans in the Golgi apparatus (data not shown).
ACE NQ is not cleaved by a batimastat-sensitive secretase
The ability of the secretase inhibitor batimastat to block the release of wtACE and ACE NQ from the IMR32 cells was assessed ( Table 1) . As compared to untreated cells, batimastat significantly inhibited (81%) the release of wtACE into the medium, with a concomitant increase in the amount of activity detected in the membrane fraction, consistent with previous results (8) .
Surprisingly, no ACE activity could be detected in the membranes from the cells expressing ACE NQ , and batimastat failed to significantly inhibit the release of this mutant form of the protein into the medium. No ACE activity was detected in the total cellular membrane fraction from the untreated cells expressing ACE NQ even after an eight times longer incubation period with the substrate BzGly-His-Leu (data not shown). Incubation of the cells expressing ACE NQ with the serine protease inhibitor DCI reduced the secretion of the protein into the medium by 75%, with a concomitant increase in activity detected in the membrane sample. Interestingly, DCI appeared to stimulate the release of wtACE into the cell medium, with a concomitant decrease in the membrane fraction. This is consistent with a previous observation (27) , although the mechanism responsible for this increased shedding is not known.
ACE NQ is cleaved in the ER
The failure to detect ACE NQ enzymic activity in the total cellular membrane fraction (Table 1) suggested that this mutant form of ACE may be cleaved soon after synthesis in the ER. To the proteins beyond the ER (Fig. 4A) . ACE NQ was susceptible to deglycosylation with EndoH indicating that it was in the high mannose form. Phase separation in Triton X-114 was used to determine whether ACE NQ retained in the ER by the temperature block lacked the hydrophobic membrane anchoring domain (Fig. 4B) . Although a significant amount of newly synthesised ACE NQ was detected in the detergent-rich pellet, possibly because the 15 o C treatment impaired the activity of the DCI-sensitive protease, a significant amount of a smaller form was also present in the detergent-poor supernatant, consistent with removal of the C-terminal membrane anchoring and cytosolic domains by an activity within the ER.
ACE NQ is cleaved at a different bond in the juxtamembrane stalk to wtACE
The cleaved forms of both wtACE and ACE NQ were purified from the conditioned medium of transfected cells by chromatography on lisinopril-2.8 nm-Sepharose (25) . The purified proteins were digested with endoproteinase Lys-C and subjected to MALDI-TOF mass spectrometry.
Mass spectrometric analysis of wtACE secreted from the IMR-32 cells revealed a peak at m/z 1690.8 (Table 2) , identical to the calculated m/z for the peptide Leu625 to Arg638. This is consistent with the normal secretase cleavage site between Arg638 and Ser639 and is in agreement with the site of cleavage seen in ACE secreted from other cells and in serum (9) . In contrast, analysis of the HPLC fractionated Lys-C digest of ACE NQ revealed a major peak at m/z 1406.3 (Table 2) , which likely represented the peptide Leu625-Asn 635 (m/z 1406.3; calculated m/z 1390.5 -the increase in mass is due to the oxidation of Trp632). The identity of this peptide was confirmed by partial N-terminal sequencing. Thus, the major site of cleavage was at the Asn635-Ser636 bond, three residues on the N-terminal side of the normal Arg638 and Ser639 cleavage site (see Fig. 1 ). There was also evidence for secondary trimming of the C-terminus of the soluble form of ACE NQ , to Trp632.
Discussion
The Asn to Gln point mutation in the juxtamembrane stalk of ACE clearly results in more efficient cleavage and secretion of the protein. At first sight this could be attributed to the mutation making ACE NQ a better substrate for the batimastat-sensitive, cell surface metallosecretase. However, closer inspection clearly shows that the shedding of ACE NQ is due to the action of a spatially and mechanistically distinct secretase. The serine protease cleaving ACE NQ is acting in the ER and cleaves ACE at a different bond in the stalk region to the normal secretase. Interestingly a mutant form of ACE, ACE-JGL, in which the stalk region had been replaced with a Ser/Thr-rich sequence that was partially O-glycosylated, was observed to be secreted from Chinese hamster ovary cells more rapidly than wtACE and its shedding was not blocked by the hydroxamic acid-based compound TAPI (27) . Like ACE NQ , the shedding of ACE-JGL was blocked by DCI, however, it was not determined whether cleavage of this mutant occurred intracellularly. The major serine proteases in the secretory pathway are the family of proprotein convertases, including furin, which are involved in the proteolytic processing of a variety of secreted and membrane-bound proteins (30) . However, this family of proteases shows a specificity for cleaving after dibasic or monobasic sequences and the cleavage site in ACE NQ does not fit this specificity (see Fig. 1 ). Also, the active forms of the proprotein convertases are located primarily in the trans-Golgi network rather than in the ER.
The effect of the Asn631 to Gln mutation invoking a distinct secretase is in contrast to a recent report where a different point mutation in the juxtamembrane stalk of somatic ACE, associated with a variation in the levels of soluble ACE in plasma, resulted in enhanced cleavage by a metallosecretase (31) . In that case mutation of Pro1199 in human somatic ACE (equivalent to Pro634 in the ACE construct used in the present study, see mutant was blocked by the hydroxamate-based metallosecretase inhibitor compound 3, the precise site of cleavage was not determined. Those authors (31) proposed that a local conformational modification caused by the Pro to Leu mutation, leads to better accessibility of the stalk region to the normal ACE secretase, resulting in the enhancement of the cleavage/secretion process. Secondary structure predictions of wild type ACE using the JPred WWW site (http://jura.ebi.ac.uk:8888/) indicated that the region from Leu620 to Asp657 is predicted to be a flexible loop, bounded by an α-helix on the N-terminal side and the transmembrane α-helix on the C-terminal side. Mutation of Asn631 to Gln had no affect on the secondary structure prediction, suggesting that the observed difference in cleavage of ACE NQ is not due to a dramatic change in secondary structure. However, it is possible that the mutation promotes binding to the serine protease either directly (Gln is a larger side chain and may be able to make more favourable contacts with the enzyme) or indirectly (by allowing the loop to adopt a more favourable conformation for binding).
The residue mutated in the present study, Asn631, lies in a potential N-glycosylation sequon (Asn-Trp-Thr-Pro), raising the possibility that this residue is glycosylated, such that its mutation to Gln prevents glycosylation and exposes a site, that is normally obscured by the glycan chain, to cleavage by a serine protease within the ER. However, this explanation appears unlikely on four counts. 1) Trp in the middle position of the N-glycosylation sequon has been shown to severely reduce the efficiency of glycosylation of the preceding Asn, while a Pro following the sequon prevents N-glycosylation altogether (32, 33) . 2) Consistent with this there is no evidence for glycosylation of this Asn residue in the mature form of either human somatic or testicular ACE ( (27, 34) and Table 2 ). 3) In rabbit ACE this potential glycosylation site is absent, yet the enzyme is cleaved by a hydroxamic acid-sensitive metallosecretase (6). 4) Attempts to mimic the effect of the Asn to Gln mutation in wild type ACE by incubation of cells with tunicamycin, 13 which blocks formation of the core dolichol-linked oligosaccharide thus preventing Nglycosylation taking place, failed to lead to secretion of wtACE in a batimastat-insensitive manner (data not shown).
An interesting feature of the ACE NQ mutant is the dramatic increase in its transport kinetics and maturation rate along the secretory pathway as compared to the membrane-bound wild type protein.
In fact, attainment of complex glycans on ACE NQ occurs at a rate that is almost threeorders of magnitude greater than that of wtACE. In general it is unlikely that non-anchoring of a protein leads per se to a higher efficiency in its intracellular transport relative to its anchored counterpart. This view is supported by several examples of proteins from which the transmembrane domains have been eliminated. Membrane-bound intestinal sucrase-isomaltase, for instance, exhibits similar transport kinetics as its soluble anchorless isoform (35) . Likewise, deletion of the transmembrane domain in the neurotrophin receptor has no implications on the intracellular transport of the mutant protein (36) . Furthermore, there is no general rule that anchorless proteins are more rapidly transported along the secretory pathway than membranebound ones. Indeed, with certain proteins the reverse appears to be the case. For example, deletion of the membrane-anchoring domain from the murine prion protein results in the secreted form of the protein reaching the cell surface at a four-fold slower rate than the wild type protein (37) and the soluble form of the Trypanosome variant surface glycoprotein is also trafficked at a slower rate than the membrane-bound form (38) .
The main rate-limiting step in the transport of membrane and secretory proteins from the ER to the Golgi apparatus is their acquisition to a correct folding and transport-competent quaternary structure in the ER (for a review see 39) . In this respect oligomerisation in the ER constitutes for many proteins a crucial criterion before they exit this organelle. This event has been shown to 
